Newborn screening for biochemical genetic disorders stands ready to expand coverage to an increasing number of disorders with the application of tandem mass spectrometry. Currently, only a few states have authorized such screening while most others await information on its public health implications. The primary objective of this study, first begun in 1999, is to compare newborn identification by expanded screening to clinical identification in children with biochemical genetic disorders in terms of the health and development of affected children and psychosocial consequences for families. The study also assesses the impact of a false positive screen compared to a normal screen in terms of parental response and interactions with the healthcare system. ? ? Continuation of this study increases the sample size of children with similar disorders and permits comparisons of children at similar ages, since clinically diagnosed children generally come to attention later than newborn-screened children. The longer-term implications for families can also be assessed. As a supplement to the earlier study, cost effectiveness analyses will be incorporated to quantify the projected health benefits, health risks and costs of expanded newborn screening, including quality of life measures (utilities) associated with false positive test results. ? ? Mothers and fathers of infants diagnosed with metabolic disorders through expanded newborn screening in Massachusetts, Maine and Pennsylvania and parents of children diagnosed with the same set of metabolic disorders in New England States, where expanded newborn screening has not been authorized, will participate in the study. Six months after the diagnosis is confirmed, parents are interviewed and children are administered a medical and neurodevelopmental evaluation. Follow-up interviews and child assessments are administered annually. Mothers and fathers of infants screened false positive (due to an initial specimen in which an abnormality is found but which does not ultimately indicate a disorder) and a control group (parents randomly selected form the public birth registry) are interviewed over the phone when their infants are 6 months old. Primary data from parent interviews and the New England Newborn Screening Program, as well as secondary data from published reports and a panel of experts will be used as inputs to the cost-effectiveness model. ? ?

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Research Project (R01)
Project #
5R01HG002085-05
Application #
6759359
Study Section
Special Emphasis Panel (ZRG1-ELSI-1 (90))
Program Officer
Thomson, Elizabeth
Project Start
2000-05-01
Project End
2006-03-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
5
Fiscal Year
2004
Total Cost
$577,327
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Prosser, Lisa A; Kong, Chung Yin; Rusinak, Donna et al. (2010) Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics 125:e286-94
Lipstein, Ellen A; Perrin, James M; Waisbren, Susan E et al. (2009) Impact of false-positive newborn metabolic screening results on early health care utilization. Genet Med 11:716-21
Waisbren, S E; Levy, H L; Noble, M et al. (2008) Short-chain acyl-CoA dehydrogenase (SCAD) deficiency: an examination of the medical and neurodevelopmental characteristics of 14 cases identified through newborn screening or clinical symptoms. Mol Genet Metab 95:39-45
Prosser, Lisa A; Ladapo, Joseph A; Rusinak, Donna et al. (2008) Parental tolerance of false-positive newborn screening results. Arch Pediatr Adolesc Med 162:870-6
Lawson-Yuen, Amy; Levy, Harvey L (2006) The use of betaine in the treatment of elevated homocysteine. Mol Genet Metab 88:201-7
Waisbren, Susan E (2006) Newborn screening for metabolic disorders. JAMA 296:993-5
Smith, Sharon E; Kinney, Hannah C; Swoboda, Kathryn J et al. (2006) Subacute combined degeneration of the spinal cord in cblC disorder despite treatment with B12. Mol Genet Metab 88:138-45
James, Philip M; Levy, Harvey L (2006) The clinical aspects of newborn screening: importance of newborn screening follow-up. Ment Retard Dev Disabil Res Rev 12:246-54
Marsden, Deborah; Larson, Cecilia; Levy, Harvey L (2006) Newborn screening for metabolic disorders. J Pediatr 148:577-584
Waisbren, Susan E; Albers, Simone; Amato, Steve et al. (2003) Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 290:2564-72

Showing the most recent 10 out of 13 publications